VTv Therapeutics: Cadisegliatin's Phase 3 CATT1 Readout Is The Next Catalyst [Seeking Alpha]
vTv Therapeutics Inc. - Class A (VTVT)
Last vtv therapeutics inc. - class a earnings: 7/31 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vtvtherapeutics.com
Company Research
Source: Seeking Alpha
Cadisegliatin's Phase 2 SimpliciT-1 showed HbA1c improvement, fewer severe hypoglycemia events, and favorable safety. In my view, this positions the stock favorably ahead of the upcoming Phase 3 data. The FDA previously put this asset on clinical hold, but VTVT has resolved that issue. CATT1 is now shortened to six months, which I infer improves its timeline as well and makes it a clear-cut catalyst in 2026. VTVT's financials also show they have enough runway to see them through this catalyst. This is why I feel it's a good time to lean bullish on the stock. AzmanL/E+ via Getty Images vTv Therapeutics Inc. ( VTVT ) is a late clinical-stage biopharmaceutical company that focuses on the development of therapies for Type 1 Diabetes (T1D), Type 2 Diabetes (T2D), and other chronic conditions. Its flagship candidate is Cadisegliatin (TTP399), an oral glucokinase activator being This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative
Show less
Read more
Impact Snapshot
Event Time:
VTVT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VTVT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VTVT alerts
High impacting vTv Therapeutics Inc. - Class A news events
Weekly update
A roundup of the hottest topics
VTVT
News
- vTv Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- vTv Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswire
- vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737GlobeNewswire
- vTv Therapeutics (NASDAQ:VTVT) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $49.00 price target on the stock, up previously from $40.00.MarketBeat
- vTv Therapeutics (NASDAQ:VTVT) was upgraded by analysts at Roth Mkm to a "strong-buy" rating.MarketBeat
VTVT
Earnings
- 5/15/25 - Miss
VTVT
Sec Filings
- 2/26/26 - Form 8-K
- 2/18/26 - Form 4
- 2/18/26 - Form 4
- VTVT's page on the SEC website